Market Spotlight: Acne
This Market Spotlight report covers the Acne market, comprising key pipeline and marketed
drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease
prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific
revenue forecasts.recasts.
Key Takeaways
Datamonitor Healthcare estimates that in 2016, there were approximately 615 million
prevalent cases of acne worldwide, and forecasts that number to increase to 673 million
prevalent cases by 2025.
Approved drugs in the acne space target retinoic acid receptor, bacterial ribosome, bacterial
protein synthesis, dihydropteroate synthetase, steroid 5a-reductase, estrogen receptor
alpha, estrogen receptor beta, folate receptor, mineralocorticoid receptor, and progesterone
receptor. These are commonly administered via the oral and topical routes.
The majority of industry-sponsored drugs in active clinical development for acne are in
Phase II.
Therapies in mid-to-late-stage development for acne focus on a variety of targets. The
majority of the drugs in mid-to-late-stage development for acne are administered via the
topical route, with the remainder being oral, subcutaneous and intravenous.
High impact upcoming events for drugs in the acne space include topline Phase II and Phase
III trial results. There were 21 licensing and asset acquisition activities involving acne drugs
during 2012–17, seven of which occurred in 2014. The $50m license agreement between
Actavis (now Allergan) and Mayne Pharma, pursuant to which Actavis will divest the US
rights to Doryx brand acne treatment and related assets to Mayne, was the largest deal
during the 201217 period.
Yaz’s sales ranked highest among drugs available for acne during 2012–16. The clinical
trials distribution across Phase I–IV indicates that the majority of trials for acne have been
in late phases of development, with 55% of trials in Phase III–IV, and 45% in Phase I–III.
The US has a substantial lead in the number of acne clinical trials globally. Germany leads
the major EU markets, while Japan has the top spot in Asia.
GlaxoSmithKline has the highest number of completed clinical trials for acne
Exclusive Sample Report @
Major Table of Contents
1 KEY TAKEAWAYS
2 DISEASE BACKGROUND
https://www.reportsworldwide.com/enquiry?report_id=42607